Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference
Aileron Therapeutics, Inc. is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Aileron's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Currently, LTI-03 is being evaluated in a Phase AUSTIN, Texas, July 30, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024 at 4:00 p.m. EDT in Boston, MA.
医疗公司Aileron Therapeutics，Inc.（"艾勒隆"）（纳斯达克：ALRN）致力于推进一系列突破性首创药物的开发，以满足孤儿肺部和纤维化疾病领域的重大未满足医疗需求。2024年8月13日星期二下午4点，在马萨诸塞州波士顿，总裁兼首席执行官Brian Windsor博士将在Canaccord Genuity第44届年度成长会议上发表演讲。
A live webcast of the event can be accessed at . A replay of the webcast will be available for 90 days following the presentation.
现场网络直播可以访问。演讲后90天内，网络直播的重播将可用。
About Aileron Therapeutics
关于Aileron Therapeutics
Aileron Therapeutics, Inc. is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Aileron's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Currently, LTI-03 is being evaluated in a Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis. Aileron's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US.
全球货币 (ALRN) 制药公司Aileron Therapeutics正在推进首批用于治疗孤儿肺部疾病和纤维化的一流药物，这是一种全新的合成肽，具有针对肺泡上皮细胞生存和受限制的纤维信号的双重机制。目前，该药物正在接受I期临床试验，用于治疗特发性肺纤维化。Aileron的第二款产品候选药LTI-01是一种酶前体，已完成了用于治疗局限性胸膜渗出液的I期b和IIa临床试验。LTI-01已在美国和欧盟获得孤儿药物认证，并在美国获得了快速通道认证。
Investor Relations & Media Contact:
Argot Partners
[email protected]
212-600-1902
投资者关系和媒体联系人：
阿哥特合伙人。
[email protected]
212-600-1902
SOURCE Aileron Therapeutics, Inc.
Aileron Therapeutics, Inc的消息来源。
